Incremental peritoneal dialysis: a 10 year single-centre experience by Sandrini, Massimo et al.
ORIgINAL ARTICLE
  Massimo Sandrini
sandrinimassy@libero.it
1 O.U. of Nephrology, A.S.S.T. Spedali Civili di Brescia, 
Piazzale Spedali Civili, 1, 25123 Brescia, Italy
2 Università di Brescia, Brescia, Italy
Received: 25 June 2016 / Accepted: 11 August 2016 / Published online: 31 August 2016
© The Author(s) 2016. This article is published with open access at Springerlink.com
Incremental peritoneal dialysis: a 10 year single-centre experience
Massimo Sandrini1  · Valerio Vizzardi1 · Francesca Valerio1 · Sara Ravera2 · 
Luigi Manili1 · Roberto Zubani1,2 · Bernardo J. A. Lucca2 · Giovanni C carini1,2
J Nephrol (2016) 29:871–879
DOI 10.1007/s40620-016-0344-z
output (0.392; p = 0.034). Hospitalization rates were sig-
nificantly lower in incrPD (p = 0.021). Eight of 29 incrPD 
patients were transplanted before reaching full dose 
treatment.
Conclusions IncrPD is a safe modality to start PD; com-
pared to stPD, it shows similar survival rates, significantly 
less hospitalization, a trend towards lower peritonitis inci-
dence and slower reduction of renal function.
Keywords Incremental dialysis · Peritoneal dialysis · 
Dialysis adequacy· R sidual renal function
Introduction
Incremental dialysis consists in prescribing a dialysis dose 
aimed at maintaining total solute clearance near the targets set 
by guidelines. In peritoneal dialysis (PD), the total amount of 
blood purification is equivalent to the sum of residual renal 
function plus the peritoneal dialysis dose [1, 2]. This makes 
it possible to start dialysis at less than full dose when there is 
still a significant renal function; afterwards, the dialysis dose 
is gradually increased to compensate renal function decline 
and to meet adequacy targets [3, 4].
The incremental approach to peritoneal dialysis (incrPD) 
was first developed in the late 90s. At that time and for many 
of the following years, however, incrPD was sometimes 
mistakenly presented as a way to start dialysis earlier [3–8]. 
Moreover, shifting consensus regarding the timing of dialy-
sis initiation has increased confusion between “incremental” 
and “early” dialysis [9, 10]. In 2006, the Kidney Disease 
Outcomes Quality Initiative (KDOQI) guidelines suggested 
that nephrologists should ev luate the benefits, risks, and 
disadvantages of beginning kidney replacement therapy 
when g omerular filtration rate (GFR) is <15 ml/min [11]; 
Abstract
Introduction Incremental dialysis co sists in prescribing a 
dialysis dose aimed towards maintaining tot l solute clear-
ance (renal + dialysis) near the targets set by guidelines. 
Incremental peritoneal dialysis (incrPD) is defined as one or 
two dwell-times per day on CAPD, wherea  standard peri-
toneal dialysis (stPD) consist  in three-four dwell-tim s per 
day.
Patients and methods Single-centre cohort study. Enrol-
lement period: January 2002–Dec mbe  2007; end of fol-
low up (FU): December 2012. Inclusion criteria: incident 
patients with FU ≥6 months, initial residual renal function 
(RRF) 3–10 ml/min/1.73 sqm BSA, renal indication for PD.
Results Median incrPD duration was 17 months (I–III Q: 
10; 30). There were no statistically significant differences 
between 29 patients on incrPD and 76 on stPD regarding: 
clinical, demographic and nthropometric characteristics at 
the beginning of treatment, adequacy indices, peritonitis-
free survival (peritonitis inc de c : 1/135 months-patients 
in incrPD vs. 1/52 months-patients n stPD) and patient 
survival. During the first 6 months, RRF remained stable 
in incrPD (6.20 ± 2.02 vs. 6.08 ± 1.47 ml/min/1.73 sqm 
BSA; p = 0.792) whereas it decreased in stPD (4.48 ± 2.12 
vs. 5.61 ± .49; p < 0.001). Patient survival was affected 
negatively by ischemic cardiopathy (HR: 4.269; p < 0.001), 
peripheral and cerebral vascular dise se (H2.842; p = 0.006) 
and cirrhosis (2.982; p = 0.032) and positively by urine 
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exported anonymously to an Excel (®Microsoft, Redmond, 
WA, USA) file: age, sex, primary renal disease, comorbidi-
ties, weight and body mass index, RRF and class of perito-
neal permeability according to a modified 3.86 % peritoneal 
equilibration test (PET) done about 3 months after the 
beginning of PD. Other data exported were: time on PD, 
adequacy parameters, incidence of peritonitis, hospital-
ization rate and outcome. RRF was measured monthly in 
incrPD patients and quarterly in stPD patients. The com-
parison of adequacy values between incrPD and stPD was 
made at baseline, after 6 months and at the end of PD or 
when transition from incrPD to stPD took place.
Statistical analysis
Continuous data are expressed as mean ± standard deviatio
(SD) or median and interquartile range (I–III Q) according 
to their distribution. Comparisons were performed using 
Student’s t test or Wilcoxon test as appropriate. Dichoto-
mous variables were analyzed using the Chi square test. A 
p value <0.05 was considered as statistically significant. 
Comparison of survival was done by Kaplan–Meier curves 
and log-rank test. Multivariate analysis was done by Cox 
proportional hazards model. The statistical program used 
was SPSS® version 19 (SPSS Inc., Chicago, IL, USA).
Results
Baseline data
The total number of incident patients in PD in 2002–2007 
was 178, of whom 39 had a follow-up <6 months, 28 had 
a RRF <3 ml/min, at start, 5 a non-renal indication for PD, 
and 1 patient was lost to follow-up. As a consequence, the 
eligible patients were 105: 42 (40 %) were women and 63 
(60 %) men; 29 (28 %) were in the incrPD group and 76 
(72 %) in the stPD group; 57 (75 %) patients of the stPD 
group were on APD and 19 (25 %) were on CAPD. Main 
baseline data of the two groups are reported in Table 1: no 
statistically significant difference was found regarding age, 
gender, weight, body mass index, comorbidity, primary 
renal disease, RRF or class of peritoneal permeability.
Change of PD modality
Median duration of incrPD was 17 months (I–III Q: 10; 
30); 21 incrPD patients shifted to stPD after a median of 
17 months (I–III Q: 10; 27). Causes of transition were a 
reduction in RRF in 19 patients and abdominal hernia in 
two. Eight patients stopped PD: 5 due to renal transplanta-
tion and 1 due to recovery of renal function; 2 patients died. 
Median duration of stPD was 36 months (I–III Q: 18; 55); 
in 2013, dialysis initiation was ecommended whenever the 
patient becomes symptomatic (independently of GFR) [12]; 
in 2014, instead, it was advised to start dialysis when GFR 
is <15 ml/min/1.73 m2 body surface area (BSA) and/  the 
patient becomes symptomatic, but, in any case, before GFR 
falls to 6 ml/min/1.73 m2 BSA [13]
A comparison between the results of incrPD as opposed 
to standard PD (stPD) (full dose) must be done using similar 
GFR values and excluding cases with an early start of dialy-
sis or with an extra-renal ind cation for dialysis (i.e. heart 
failure and end-stage liver disease). The first clinical experi-
ences with incrPD date back to 1999–2002 [7, 8, 14, 15]; 
initial prescription consisted of 1–2 dwell-times per day. In 
2003, incremental automated peritoneal dialysis (APD) was 
suggested; it consisted of a full daily dose of APD, but only 
for 3–4 nights per week [16].
Based on these reports, in 2002 we st rted an incrPD 
program. This paper analyzes our clin cal experience nd 
attempts to provide further informati n regardi g this new 
approach to the start of dialy is.
Patients and methods
This cohort study attempts to define the results of the incre-
mental PD approach. All patients who started PD from 
January 1st 2002 to December 31st 2007 in our center 
were included. End of follow-up was December 31st 2012, 
or when the patient stopped PD because of death, shift to 
hemodialysis (HD), renal transplantation or recovery of 
renal function.
Residual renal function (RRF) was measured as the mean 
of creatinine renal clearance and urea renal clearance. Inclu-
sion criteria were as follows: follow-up lasting at least 6 
months, RRF at start of PD >3 ml/min/1.73 m2 BSA and 
<10 ml/min/1.73 m2 BSA and a “renal ind cation” for PD. 
Standard dialysis dose (stPD) was defined as 3–5 dwell-
times per day, 7 days a week, for continuous ambulatory 
peritoneal dialysis (CAPD) and nightly dialysis sess ons, 
seven nights a week, for APD. Increm nt l dialysis dose 
(incrPD) was defined as one or two dwell times per day on 
CAPD.
The eligible patients wer  ivided into two groups 
according to the dialysis dose with which they started: 
stPD or incrPD. Choice of PD modality, either CAPD or 
APD, was made according to patient preference following 
adequate information and exclusion of clinical contraindica-
tions. IncrPD was suggested only to patients who had cho-
sen CAPD, because at that time incremental APD had not 
been defined yet.
All demographic and clinical data were prospectively 
recorded in a database (File Maker®, File Maker Inc., 
Santa Clara, CA, USA). The following baseline data were 
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of 1/58 over a follow-up period of 2267 patient-months. 
The incidence of peritonitis was 1/39 on CAPD vs. 1/49 on 
APD when all periods at risk were taken into consideration. 
Even though the absolute incidence was quite different, the 
cumulative probability of being peritonitis-free (log-rank 
test on Kaplan–Meier curves) showed no significant differ-
ence between incrPD and stPD or between CAPD and APD.
Hospitalization
Among the patients on incrPD, 30 admissions occurred in 
677 patient-months (1/23 patient-months) for a total of 322 
days of hospitalization (5.7 days/patient-years). Among 
the patients on stPD there were 325 admissions in 2932 
patient-months (1/9 patient-months) and 3784 days of hos-
pitalization (15.5 days/patient-years). At the “as treated” 
analysis, the cumulative probability to be hospitalization-
free was higher in the incrPD group than in the stPD group 
(p = 0.021) (Fig. 1); only 20 % of the stPD patients were 
hospitalization-free after 24 months vs. 45 % of the incrPD 
group.
Patient survival
At the end of the follow-up, 41 patients (40 %) had died. In 
the incrPD group, 2 patients died of peritonitis, 1 died due 
to sepsis/severe infection, 2 due to ischemic heart disease, 
1 due to a stroke, 2 due to cachexia and 1 died due to hem-
orrhagic shock. In the stPD group, 3 patients died of peri-
tonitis, 12 patients died of sepsis/severe infections, 3 from 
ischemic heart disease, 1 from stroke, 4 due to cachexia, 1 
of malignancy, 6 due to other causes and in two cases the 
cause of death was unknown. Patient survival was not sig-
nificantly different between incrPD and stPD, according to 
both the “as treated” and the “intention to treat” analysis 
(Fig. 2). The Cox hazards regression model was applied to 
identify those factors (PD modality, age, sex, comorbidity, 
RRF and urine output) significantly affecting patient sur-
vival. Ischemic cardiopathy, peripheral and cerebral vascu-
lar disease and cirrhosis (the latter only with “as treated” 
analysis) were detrimental factors. On the contrary, urine 
output significantly improved survival (Table 4). PD modal-
ity did not affect survival.
Discussion
The basic assumption of incremental dialysis is to reach 
the minimal targets for adequate dialysis by summing 
renal function and dialysis dose. Mehrotra et al. and Gol-
per first described an early and incremental approach to 
peritoneal dialysis [3,4]. Some clinical experiences in 
incrPD were reported in the 90s; the main features of those 
5 patients shifted from CAPD to APD, two because of p r-
sonal choice, two due to abdominal hernias and one because 
of inadequate dialysis. A total of 69 stPD patients stopped 
PD: 27 (39 %) due to renal transplantation, one (1 %) recov-
ered renal function, 10 (14 %) shifted to HD and 32 (46 %) 
died.
Adequacy data
A comparison of dialysis adequacy data is shown in Table 2: 
total (renal + peritoneal) wKt/V (twKt/V) and wClCr 
(twClCr) at the beginning, after 6 months and at the end of 
the treatment. Student’s t test for paired sampl s was carried 
out only between initial data and the 6th month, sin e at 
the end of treatment the f llow-up periods wer dramati-
cally different among patients. At the sixth month Kt/V and 
wCrCl were significantly lower in stPD (p = 0.012 and 0.004, 
respectively), but stable in incrPD (p = 0.672 and 0.485). 
The changes were associated with a significant reduction of 
the renal contribution to both th ur a and creat nine clear-
ance in stPD (p <0.001 for both), whereas c ang s were no  
statistically significant in incrPD.
Changes in peritoneal cleara ces occurring in stPD 
mainly depended on changes i  the pres rib d dose of 
dialysis.
Incidence of peritonitis
During a total follow-up of 4603 patien -months, 91 epi-
sodes of peritonitis occurred, with an incidence of 1/51 
patient-months. When considering only the time spent on 
the first modality, incrPD or stPD, the incidence of perito-
nitis was 1/135 patient-months in the incrPD group vs. 1/52 
patient-months in the stPD group (Table 3). If all periods at 
risk are taken into consideration, the incidence f peritonitis 
in the stPD group becomes 1/46 patient-months (Table 3). 
In the stPD group, the 19 pati nts on CAPD h  a fo low-
up of 665 patient-months with an incidence f per tonitis of 
1/39, while the 57 on APD had an incidenc of peritonitis 
Table 1 Baseline data of the two groups: incrPD and stPD
incrPD stPD p
Number of patients29 76
Male gender 13 (55 %) 50 (66 %) 0.611
Age (years) 63 ± 12 59 ± 18 0.200
Weight (Kg) 63.4 ± 10.2 62.8 ± 16.7 0.837
BMI (Kg/m2) 24.3 ± 3.9 23.3 ± 3.7 0.130
RRF (ml/min/1.73 m2 BSA) 5.74 ± 1.34 5.42 ± 1.75 0.381
D/P creatinine 4th hour0.63 ± 0.14 0.62 ± 0.11 0.426
incrPD incremental peritoneal dialysis, stPD standar  peritoneal 
dialysis, BMI body mass index, RRF residual renal functio , BSA 
body surface area, D/P di lysate/plasma
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cost reduction and increased PD penetration; it is also con-
sidered as an ideal bridge to renal transplantation.
Our experience with incrPD began in the late 90s and 
is based on two assumptions: (a) advanced renal failure 
and renal replacement therapy are a continuum and should 
be treated as such [18]; (b) in accordance with the stud-
ies regarding peritoneal dialysis adequacy [2], total blood 
purification is considered as the sum of renal and peri-
toneal clearance, even though they have different blood 
purification profiles. Furthermore, we have to clarify the 
enrolment modality: the choice of PD modality between 
CAPD and APD, as well as between incrPD and stPD, 
was up to the informed patient (in the absence of clinical 
contraindications). The incremental approach was sug-
gested only to patients who had chosen CAPD because, 
at that time, incrAPD had not been recommended in the 
studies are summarized in Table 5. The aforementioned 
studies enrolled only a few patients, without a ontrol 
group and without any stat tical c mparison. De Vecchi 
et al. first reported working activity, degree of rehabilita-
tion and quality of life in incrPD patients; quality of life 
and social rehabilitation w re better preserved wi h ncrPD 
than with stPD [15].
As of today, there are no papers which delineate the 
features, efficacy, feasibility and safety of incrPD. Despite 
these considerations, incrPD is used more and mor  often: 
in Italy, 54 % of PD centers use incrPD and 29 % of patients 
start PD with the incremental approach [17]. The hypotheti-
cal benefits of incrPD may explain its widespread use: better 
quality of life, reduced glucos  exposi ion, better peritonitis-
free survival, longer preservation of residual renal function, 
Table 3 Prevalence of peritonitis in the two groups of patients: incrPD 
and stPD
Only first treatment Number of patients29 76
Follow-up (patient-months) 677 2932
Number of peritonitis 
episodes
5 56
Peritonitis incidence 
(episode/patient-months)
1/135 1/52
Overall Number of patients29 110
Follow-up (patient-months) 677 3926
Number of peritonitis 
episodes
5 86
Peritonitis incidence 
(episode/patient-months)
1/135 1/46
Overall: calculated over the entire follow-up period according to the 
modality in use at that time and considering the patient who changes 
modality as a new patient
Log-rank test: p = 0.021
100
80
60
40
20
0
Follow-up (months)
48240 12 36 60
incrPD
stPD
C
um
ul
at
iv
e 
su
rv
iv
al
 fr
om
 h
os
pi
ta
liz
at
io
n 
(%
)
Fig. 1 Cumulative probability to be hospitalization-free in incrPD and 
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a median duration of incrPD of 17 months, which could 
positively affect the patients’ quality of life on PD due to 
a lesser burden of dialysis procedures. On this ground it 
is also clear that patients on incrPD need a closer clini-
cal follow-up to reduce the risk of under-dialysis; in our 
center, RRF was measured monthly and total clearances 
quarterly in incrPD.
Peritonitis is a major complication of PD and remains an 
important cause of drop-out. According to the recommen-
dations of the International Society for Peritoneal Dialysis, 
the peritonitis rate should be lower than one episode every 
18 months. In the literature regarding incrPD, peritonitis 
rates range from zero (follow-up: 84 patient-months) to 
one episode/21 patient-months (Table 5). De Vecchi et a . 
reported that the risk of peritonitis was associated to the 
number of exchanges [15]. In our study the peritonitis rate 
was 1/135 patient-months in the incrPD group and 1/52 
patient-months in the stPD group (Table 3). The reduced 
number of connections and the “dry” period could have 
played a role in reducing the peritonitis rate in incrPD 
even though it was not statistically significant according 
to the Kaplan–Meier curves. On the other hand, the low 
frequency of exchanges of APD, in incrPD, could reduce 
patient experience, increase the risk of errors and, conse-
quently, the occurrence of peritonitis. According to our 
results, however, this effect does not appear to be so impor-
tant. Hospitalization-free survival was significantly better 
in the incrPD group than in the stPD group; however, it 
must be considered that the treatment of our patients suf-
fering from peritonitis is done on an inpatient basis. We did 
not find any papers comparing patient survival in incrPD 
vs. stPD. In our study, incrPD showed a trend towards bet-
ter survival at the “intention to treat” analysis, but it was 
marginally non-significant (Fig. 2). The Cox analysis did 
not indicate incrPD as a risk factor for mortality (Table 4). 
The data we collected do not suggest a clear survival ben-
efit with incrPD, but at least they support a non-inferiority 
of incrPD vs. stPD.
The main biases of our study are: (1) it is a retrospective, 
one-center study, and (2) the patients were not randomized. 
clinical literature. This study’s comparis vs. 
stPD was made only in those patients who had started 
dialysis before 2008 as, after the nd of 2007, the positive 
clinical results yielded by incrPD urged us to sugg s  it to 
all patients with RRF ≥3 ml/min/1.73 m2 BSA. Because 
of this, a stPD group for comparison was not available 
any more.
For a comparison between incrPD and stPD to be made, 
it is necessary that: groups of patient  are com arable, 
the start of dialysis occurs at similar values of RRF and 
patients who started PD due to non-re al indication are 
excluded. The two groups of our study wer comparabl
(Table 1). RRF at the beginning of PD, calculated as the 
mean of measured creatinine and urea cle rance, was in 
line with the guidelines in f c  a  the time of the study 
[19]. RRF was not different between the incrPD group 
and the stPD group, so incrPD was not started a  an earlier 
stage than stPD. It should be not d that to start with incrPD 
it is necessary to have a good p e-dialysis progr m and a 
timely initiation of dialysis; seve a  studi s have s own 
that a good pre-dialysis education program increases the 
prevalence of patients opting for self-care dialysis [19–
25]. As far as adequacy is conc rn d, pati nts in both the 
incrPD group and the stPD group were always above the 
minimal targets of adequacy [2] even tho gh, as expected, 
adequacy values were highe  on stPD at the beginning of 
treatment (Table 2).
It is interesting to note that total Kt/V and wCrCl  
the incrPD groups remained stable over the first 6 months, 
whereas they decreased significantly in the stPD group. 
This could be due to a better prese vat on of res dual renal 
function in incrPD both for creati ine and urea whose 
ratios did not significantly change. It should also be noted 
that the peritoneal contributio  to he total clearance is 
always higher for urea tha  for cre in e, due to dif er-
ences in the renal handling an  peritoneal permeability of 
those molecules. The results of this stud  suggest a protec-
tive role of incrPD on RRF which was stable in incrPD 
in the first 6 months whereas it significantly decreased 
in stPD (Table 2). This stability could b  he reason for 
Method Factor HR 95 % CI p
As treated Ischemic heart disease4.269 1.174–7.124 <0.001
Peripheral/cerebral vascular 
disease
2.842 1.630–9.330 0.006
Urine output (l/day)0.392 0.164–0.934 0.034
Cirrhosis 2.982 1.037–6.0257 0.032
Intention to treatIsch mic heart disease3.297 1.716–6.332 <0.001
Peripheral/cerebral vascular 
disease
3.354 1.715–6.555 <0.001
Urine output (l/day)0.387 0.181–0.826 0.014
HR hazard ratio, CI confidence interval
Table 4 R sults of the Cox 
hazard regressions on patient 
survival
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As a consequence, the results cannot be generalized. How-
ever, its results could be of some help in designing future 
multicenter randomized studies.
Conclusions
Incremental peritoneal dialysis, which must not to be con-
fused with an early start of dialysis, provides adequate dia-
lytic doses, has a reduced hospitalization rate compared to 
stPD, yields a similar patient survival to that observed with 
stPD, and is time saving for the patient. Therefore, incrPD 
is a safe modality to begin dialysis and should be offered 
to most patients with significant RRF (3–6 ml/min/1.73 m2 
BSA) at the start of dialysis. In order to obtain good compli-
ance, patients should be given adequate information about 
the future need to increase the dose of dialysis when RRF 
declines. A longer preservation of RRF could be a further 
positive effect of this modality and favor its choice among 
patients on the waiting list for renal transplantation.
Two things are necessary to start dialysis with incrPD: 
(1) a well-organized pre-dialysis outpatient clinic able to 
postpone the start of dialysis [26] as well as to “build” an 
informed and compliant patient; (2) a close clinical and lab-
oratory follow-up to avoid that a sudden reduction in RRF 
could precipitate the patient towards a condition of under-
dialysis. Moreover, last but not least, some patients could 
receive a kidney transplant while on incrPD before switch-
ing to full-dose PD. Finally, one cannot exclude than incrPD 
could favor the diffusion of PD, a dialysis modality that is 
cost-saving in comparison to HD.
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